Is ISTA a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

102 people get ISTA articles and Market Currents by email alert.

Get email alerts on ISTA »

HEADLINES:

First Merck, Then Bausch And Lomb, Who's Next To Partner With InSite Vision?
Andreas Spiro • Thu, Jul 26, 2012
Valeant: Buy This 'Spring Loaded' Stock Now
Vatalyst • Sun, Jul 1, 2012
ISTA Pharmaceuticals Stockholders Vote to Approve Acquisition by Bausch + Lomb

Marketwire (Jun 5, 2012)
ISTA Pharmaceuticals Highlights PROLENSA(TM) Clinical Data at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Marketwire (May 10, 2012)
Merger Arbitrage Mondays: May 7, 2012
Asif Suria • Mon, May 7, 2012 • 2 Comments
ISTA Pharmaceuticals Reports First Quarter 2012 Financial Results

Marketwire (May 3, 2012)
ISTA Pharmaceuticals Reports Positive, Topline Results From Its Phase 2 Clinical Trial of BEPOSONE(TM) Nasal Spray for the Treatment of Symptoms Associated With Seasonal Allergic Rhinitis

Marketwire (May 1, 2012)
Merger Arbitrage Mondays - April 30, 2012
Asif Suria • Mon, Apr 30, 2012 • 3 Comments
Bausch + Lomb and ISTA Pharmaceuticals Announce Early Termination of Hart-Scott-Rodino Waiting Period

Marketwire (Apr 23, 2012)
ISTA Pharmaceuticals Highlights PROLENSA(TM) Clinical Data at the 2012 American Society of Cataract and Refractive Surgery (ASCRS) Symposium and Congress

Marketwire (Apr 23, 2012)
Valeant Ready To Spring Higher On New Atlantis Pharma Deal
Investment Underground • Fri, Apr 20, 2012 • 1 Comment
Top Small-Cap Biotech Stocks Being Accumulated By Legendary Fund Managers
GuruFundPicks • Tue, Apr 17, 2012 • 6 Comments
Shedding A Little Light On Under-Followed DUSA Pharmaceuticals
Stephen Simpson • Mon, Apr 16, 2012
Valeant: Now A Compelling Long-Term Play
ValueMax • Thu, Apr 5, 2012
ISTA Pharmaceuticals: Cost Cutting And A $9.10 A Share Takeover Offer From Bausch & Lomb
Roy Manning III • Fri, Mar 30, 2012
9 Outperforming Small-Caps Undervalued By EPS Trends
Kapitall • Thu, Mar 29, 2012 • 1 Comment
ISTA Pharmaceuticals Gets The Bid It Wants
Stephen Simpson • Tue, Mar 27, 2012
ISTA Pharmaceuticals Announces Issuance of U.S. Patent for PROLENSA(TM)

Marketwire (Mar 27, 2012)
Bausch + Lomb to Acquire ISTA Pharmaceuticals

Marketwire (Mar 26, 2012)
ISTA Pharmaceuticals Announces Settlement on Royalty Dispute

Marketwire (Mar 26, 2012)

To learn more about Seeking Alpha Pro, click here.

ISTA Pharmaceuticals: Cost Cutting And A $9.10 A Share Takeover Offer From Bausch & Lomb
Roy Manning III • Fri, Mar 30, 2012
ISTA Pharmaceuticals Gets The Bid It Wants
Stephen Simpson • Tue, Mar 27, 2012
Okay, ISTA Management, It's Time To Step Up
Stephen Simpson • Mon, Jan 30, 2012
Valeant Bid Opens Eyes On ISTA Pharmaceuticals' Value
Stephen Simpson • Fri, Dec 30, 2011 • 1 Comment
ISTA Shedding Tears on Remura Failure
EP Vantage • Mon, Aug 1, 2011
ISTA’s Eye Drug Shows Success
Zacks Investment Research • Wed, Aug 26, 2009
A Look at ISTA's Strong Pipeline
Dan Weiss • Wed, Jun 17, 2009 • 2 Comments

First Merck, Then Bausch And Lomb, Who's Next To Partner With InSite Vision?
Andreas Spiro • Thu, Jul 26, 2012
Valeant: Buy This 'Spring Loaded' Stock Now
Vatalyst • Sun, Jul 1, 2012
Merger Arbitrage Mondays: May 7, 2012
Asif Suria • Mon, May 7, 2012 • 2 Comments
Merger Arbitrage Mondays - April 30, 2012
Asif Suria • Mon, Apr 30, 2012 • 3 Comments
Valeant Ready To Spring Higher On New Atlantis Pharma Deal
Investment Underground • Fri, Apr 20, 2012 • 1 Comment
Top Small-Cap Biotech Stocks Being Accumulated By Legendary Fund Managers
GuruFundPicks • Tue, Apr 17, 2012 • 6 Comments
Shedding A Little Light On Under-Followed DUSA Pharmaceuticals
Stephen Simpson • Mon, Apr 16, 2012
Valeant: Now A Compelling Long-Term Play
ValueMax • Thu, Apr 5, 2012
9 Outperforming Small-Caps Undervalued By EPS Trends
Kapitall • Thu, Mar 29, 2012 • 1 Comment
Past Bouncers And Others Biotech Plays Ready To Move
MarketScanners • Thu, Jan 26, 2012 • 2 Comments
2011 Review And Outlook For Biotechnology In 2012
Michael Becker • Wed, Jan 25, 2012 • 2 Comments
Valeant's Hostile Bid For ISTA
EP Vantage • Tue, Dec 20, 2011
5 Stocks Posting Big Jumps Last Week
Alex Shadunsky • Mon, Dec 19, 2011
5 Healthcare Stocks Under $5 Poised To Rise
MarketScanners • Wed, Dec 7, 2011 • 1 Comment
17 High-Growth Healthcare Stocks Being Bought Up By Hedge Funds
Kapitall • Sun, Nov 20, 2011 • 2 Comments
20 Smart Money Stock Picks Trading Under $5
Kapitall • Thu, Nov 3, 2011 • 4 Comments
18 High-Growth Smart Money Picks Trading Under $5
Kapitall • Thu, Sep 8, 2011 • 2 Comments
5 Stocks on the Move on Friday
Alex Shadunsky • Mon, Aug 1, 2011 • 2 Comments
10 Medical Device Companies With Plenty of Upside
Inflection Point Investing LLC • Mon, Apr 18, 2011 • 2 Comments
31 Undervalued Small Caps
Rash Menaria • Mon, Apr 11, 2011 • 1 Comment

ISTA Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
Fri, Apr 30, 2010 • 1 Comment
ISTA Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript
Wed, Mar 19, 2008

ISTA Pharmaceuticals Stockholders Vote to Approve Acquisition by Bausch + Lomb

Marketwire (Jun 5, 2012)
ISTA Pharmaceuticals Highlights PROLENSA(TM) Clinical Data at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Marketwire (May 10, 2012)
ISTA Pharmaceuticals Reports First Quarter 2012 Financial Results

Marketwire (May 3, 2012)
ISTA Pharmaceuticals Reports Positive, Topline Results From Its Phase 2 Clinical Trial of BEPOSONE(TM) Nasal Spray for the Treatment of Symptoms Associated With Seasonal Allergic Rhinitis

Marketwire (May 1, 2012)
Bausch + Lomb and ISTA Pharmaceuticals Announce Early Termination of Hart-Scott-Rodino Waiting Period

Marketwire (Apr 23, 2012)
ISTA Pharmaceuticals Highlights PROLENSA(TM) Clinical Data at the 2012 American Society of Cataract and Refractive Surgery (ASCRS) Symposium and Congress

Marketwire (Apr 23, 2012)
Movers & Shakers: Tuesday’s biggest gaining & declining stocks

at MarketWatch.com (Mar 27, 2012)
Arena, Sirius active on Nasdaq; Lennar hits 52-week high

at MarketWatch.com (Mar 27, 2012)
Stocks to Watch: LEN, WAG, BIDU & More

at CNBC.com (Mar 27, 2012)
ISTA Pharmaceuticals Announces Issuance of U.S. Patent for PROLENSA(TM)

Marketwire (Mar 27, 2012)
Stocks to Watch: Stocks to watch Tuesday: Ista, Dollar General

at MarketWatch.com (Mar 27, 2012)
After Hours: Apollo Group turns lower, Ista gains after hours

at MarketWatch.com (Mar 26, 2012)
Bausch + Lomb to Acquire ISTA Pharmaceuticals

Marketwire (Mar 26, 2012)
ISTA Pharmaceuticals Announces Settlement on Royalty Dispute

Marketwire (Mar 26, 2012)
Indications: U.S. futures lower; Pep Boys, Thomas & Betts gain

at MarketWatch.com (Jan 30, 2012)
Movers & Shakers: Tuesday’s biggest gaining and declining stocks

at MarketWatch.com (Jan 17, 2012)
ISTA Pharmaceuticals Announces Adoption of a Replacement Stockholders Rights Plan

Marketwire (Jan 17, 2012)
ISTA's Board of Directors to Review Valeant's Revised Proposal as Part of Its Ongoing Review of Strategic Options

Marketwire (Jan 17, 2012)
ISTA Pharmaceuticals Announces U.S. Patent Allowance for PROLENSA(TM) in the United States

Marketwire (Jan 6, 2012)
ISTA Pharmaceuticals Announces Preliminary 2011 Revenue Results; Provides 2012 Financial Guidance and Updates Key Pipeline Milestones

Marketwire (Jan 4, 2012)

ISTA vs. ETF Alternatives

Company Description

ISTA Pharmaceuticals is a commercial stage, multi-specialty pharmaceutical company developing, marketing and selling our own products in the United States. We manufacture our products through third party contracts, and we in-license or acquire new technology to add to our internal development... More

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, July 5, 2012, 6:09 PM After going private in 2007, eye care giant Bausch + Lomb may be considering an IPO before year-end. According to reports, the company is seeking to bulk-up via acquisitions, a thesis reinforced by its recent $600M acquisition of ISTA Pharmaceuticals (ISTA). Comment! [Healthcare]
Tuesday, March 27, 2012, 9:03 AM Premarket gainers: OPXT +55%. WNC +9%. ISTA +8%. DANG +5%. RBS +3%. ARNA +3%. LEN +3%.
Losers: MAPP -17%. MMR -16%. APOL -6%. NBG -6%. TOT -6%. OCLR -3%. EXPE -3%. HEK -3%. EXXI -3%. Comment! [On the Move]
Monday, March 26, 2012, 5:57 PM Bausch + Lomb acquires ISTA Pharmaceuticals (ISTA) for $500M, or $9.10 per share in cash. The transaction is expected to strengthen Bausch + Lomb's overall product pipeline and is expected to close in 2Q12. Comment! [Healthcare, M&A]
Thursday, February 23, 2012, 5:12 PM ISTA Pharmaceuticals (ISTA): Q4 EPS of $0.25 beats by $0.04. Revenue of $45.1M (-11.7% Y/Y) misses by $1.5M. (PR) Comment! [Earnings, Healthcare]
Wednesday, February 1, 2012, 2:29 PM A SEC filing reveals that hedge fund Loeb Arbitrage holds a 5.06% stake in Ista Pharmaceuticals (ISTA +1.4%) with all the shares on record being purchased since the end of Q3. Comment! [Healthcare]
Monday, January 30, 2012, 8:06 AM Valeant Pharmaceuticals (VRX) withdraws its buyout offer of $7.50 per share for ITSA Pharmaceuticals (ISTA) due to what it calls a "lack of progress" with ISTA's management team. Shares of ISTA -8.4% premarket. Comment! [Healthcare, On the Move, M&A]
Tuesday, January 17, 2012, 9:25 AM Premarket gainers: VQ +50%. CNVO +48%. DNN +17%. PVX +15%. TSLA +15%. ISTA +11%. EK +10%. ING +8%. AEG +8%. FRO +8%. AVL +7%. QCOR +7%. BRD +6%. NBG +6%. RBS +6%. NOK +6%. TTM +5%. JASO +5%. MTL +4%. BHP +4%. SINA +4%. RIO +4%. ASML +4%. HMA +4%. WFR +4%. GMCR +3%. TSL +3%. HL +3%. AVNR +3%. HMY +3%. NDCO +3%. CLWR +3%. BIDU +3%. TOT +3%. BSBR +3%. BUD +3%. FCX +3%. CS +3%.
Losers: CUK -16%. CCL -15%. KGC -8%. RCL -7%. C -5%. MTG -5%. Comment! [On the Move]
Tuesday, January 17, 2012, 2:29 AM Valeant Pharmaceuticals (VRX) raised its offer for ISTA Pharmaceuticals (ISTA) to $7.50/share from an initial $6.50/share, and set a target price of $8.50/share subject to a week of due diligence, according to an ISTA statement. ISTA officials say they're considering the revised offer but are also in talks with other companies. (previously) Comment! [Healthcare, M&A]
Friday, January 6, 2012, 10:33 AM Shares of Valeant (VRX -2.3%) hit some volatility this morning after its 2012 guidance presentation. The company sees Q4 earnings in the mid-range of estimates, while it ups 2012 EPS estimates to between $3.95 - $4.20. More importantly, the company says there's still no agreement on the buyout process or price with Ista Pharmaceuticals (ISTA -0.4%), following Ista's rejection of its recent bid in December, and puts a drop dead date of January 31 for negotiations. Comment! [Healthcare, On the Move]
Friday, January 6, 2012, 8:03 AM ISTA Pharmaceuticals (ISTA) announces that it landed a U.S. patent allowance for Prolensa along with partner Senju Pharmaceuticals. The firm says it anticipates filing a New Drug Application with the FDA for Prolensa in H1, with a commercial launch expected in early 2013. Comment! [Healthcare]
Wednesday, January 4, 2012, 4:44 PM ISTA Pharmaceuticals (ISTA) says during its guidance and pipeline update that it expects 2012 earnings and revenue to come in below estimates. It now expects its EPS to be between $0.28 - $0.39 on revenue of around $180M -$195M. Comment! [Healthcare]
Friday, December 16, 2011, 11:09 AM The board of ISTA Pharmaceuticals (ISTA +68.1%) confirms that it rejected Valeant Pharmaceuticals' (VRX -0.5%) offer of $6.50/share, calling it "grossly inadequate." Comment! [Healthcare, On the Move]
Friday, December 16, 2011, 7:54 AM Valeant Pharmaceuticals (VRX) offers $314M or $6.50/share in cash for ISTA Pharmaceuticals (ISTA +60%), a 67% premium to Thursday's close. (PR) Comment! [M&A, Breaking News, On the Move, Healthcare]
Thursday, October 13, 2011, 1:02 PM ISTA Pharmaceuticals (ISTA -5.3%) trades lower after reporting mixed results from its eye drug trials. Phase 3 studies to evaluate the short-term safety and efficacy of its drug Remura, a treatment for dry eye disease, showed it was effective but not statistically better than the placebo. 1 Comment [Healthcare, On the Move]
Friday, July 29, 2011, 10:39 AM ISTA Pharmaceuticals (ISTA) falls 27.6% after reporting Q2 revenue and adjusted EPS of $37.1M (+6% Y/Y) and -$0.11, below a consensus of $41.9M and $0.05. Perhaps more importantly, ISTA is also reporting that a a Phase 3 study for its REMURA drug for treating dry eye disease showed that the drug "was not statistically significantly better" than a placebo. Comment! [Healthcare, On the Move, Earnings]
Monday, October 18, 2010, 9:00 AM Premarket gainers: KWK +15%. ISTA +15%. PPHM +9%. GNBT +8%. STX +6%. FBP +6%. STEM +6%. AGN +5%. PIP +5%.
Losers: PETS -13%. MMR -4%. Comment!

ISTA ISTA Pharmaceuticals, Inc.

ISTA

ISTA Pharmaceuticals, Inc.